Protalix BioTherapeutics launches at-the-market offering of up to $20M common stock at $2.08/share

Filed August 22, 2025 · ~1 min read

Key Changes

• high

  The company may sell up to $20 million of common stock from time to time through H.C. Wainwright, with $15.7 million remaining under the sales agreement.

  The Offering verify on EDGAR →
• medium

  Net proceeds are intended for general corporate purposes, including working capital and clinical trials, with broad management discretion.

  Use of Proceeds verify on EDGAR →
• high

  New investors would incur immediate dilution of $0.86 per share based on an assumed offering price of $1.58, with further dilution possible from outstanding options.

  Dilution verify on EDGAR →